A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a
A phase 2 trial of Selpercatinib in thyroid cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation is a phase 2 interventional study registered as NCT04280081 by Eli Lilly and Company, with 77 participants enrolled, started 2020-03-16 and due to reach its primary completion in 2021-03-25. Interventions recorded: Selpercatinib. Conditions listed: Solid Tumor, Medullary Thyroid Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Selpercatinib, Eli Lilly (incl. Loxo).
- PersonLori J. Wirth
Shares Selpercatinib, Thyroid cancer.
- PersonAlexander Drilon
Shares Selpercatinib, Thyroid cancer.
- TrialLIBRETTO-531
Shares Selpercatinib, Thyroid cancer.
- TreatmentPralsetinib
Shares Selpercatinib, Thyroid cancer.
- CancerMultiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.